LifeMine Raises $263 Million to Accelerate the Clinical Development of LIFE-001, a Structurally and Mechanistically Novel Calcineurin Activation Inhibitor Designed to Transform Organ Transplantation

LifeMine Announces First Participant Dosed in First-in-human Phase 1 Clinical Trial of LIFE-001, Designed De Novo to Become a Field Dominating Immunosuppressive for Immune-mediated Disorders and Transplantation

LifeMine Therapeutics Appoints Jennifer A. Jarrett to Board of Directors

Fierce Biotech names LifeMine Therapeutics as one of its “Fierce 15” Biotech Companies of 2022